0.3233
40.88%
-0.222
시간 외 거래:
.32
-0.00325
-1.01%
전일 마감가:
$0.5452
열려 있는:
$0.4344
하루 거래량:
10.47M
Relative Volume:
22.24
시가총액:
$28.55M
수익:
-
순이익/손실:
$-60.61M
주가수익비율:
-0.5388
EPS:
-0.6
순현금흐름:
$-22.91M
1주 성능:
-29.63%
1개월 성능:
-31.57%
6개월 성능:
-48.26%
1년 성능:
-78.80%
Bioline Rx Ltd Adr Stock (BLRX) Company Profile
BLRX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
BLRX | 0.3233 | 28.55M | 0 | -60.61M | -22.91M | -0.60 |
VRTX | 450.37 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 596.74 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 246.80 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 108.23 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2017-05-18 | 업그레이드 | Maxim Group | Hold → Buy |
2017-02-13 | 개시 | Rodman & Renshaw | Buy |
2016-08-12 | 다운그레이드 | Maxim Group | Buy → Hold |
2015-08-17 | 재확인 | Maxim Group | Buy |
2015-07-27 | 재확인 | ROTH Capital | Buy |
2015-06-22 | 개시 | JMP Securities | Mkt Outperform |
모두보기
Bioline Rx Ltd Adr 주식(BLRX)의 최신 뉴스
BioLineRx stock hits 52-week low at $0.38 amid market challenges - Investing.com
BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell - TipRanks
BiolineRx Ltd. Announces New Direct Offering of Shares - TipRanks
SEC Form 424B5 filed by BioLineRx Ltd. - Quantisnow
BioLineRx to Report Third Quarter 2024 Results on November 25, 2024 - Benzinga
BioLineRx Granted Extension to Meet Nasdaq Requirements - TipRanks
BioLineRx’s Motixafortide Shows Promise in Sickle Cell Trials - TipRanks
BioLineRx stock hits 52-week low at $0.39 amid market challenges - Investing.com India
BioLineRx Secures Extended U.S. Patent for Motixafortide - TipRanks
BioLineRx secures US patent for cancer drug motixafortide - Investing.com
BioLineRx secures US patent for cancer drug motixafortide By Investing.com - Investing.com UK
BioLineRx stock hits 52-week low at $0.43 amid market challenges - Investing.com
Riding the Waves: A Guide to Investing in BLRX Stock - The InvestChronicle
Market Insight: Bioline Rx Ltd ADR (BLRX)’s Notable Drop, Closing at 0.46 - The Dwinnex
BioLineRx stock hits 52-week low at $0.5 amid market challenges - Investing.com
BioLineRx Ltd. Shareholders Approve Key Resolutions - TipRanks
Bioline Rx Ltd ADR (BLRX) Stock: A Year of Market Fluctuations - The InvestChronicle
Stock Market Recap: Bioline Rx Ltd ADR (BLRX) Concludes at 0.54, a -13.53 Surge/Decline - The Dwinnex
A new trading data show Bioline Rx Ltd ADR (BLRX) is showing positive returns. - SETE News
Metric Analysis: Bioline Rx Ltd ADR (BLRX)’s Key Ratios in the Limelight - The Dwinnex
BLRX overperforms with a 0.95 increase in share price - US Post News
Australia Single Molecule, Real-Time (SMRT) Sequencing Market Size & Outlook, 2030 - Grand View Research
BioLineRx Schedules Annual Shareholders Meeting - TipRanks
Financial Analysis: Bioline Rx Ltd ADR (BLRX)’s Ratios Unveil Key Insights - The Dwinnex
BLRX Stock: Exploring Bioline Rx Ltd ADR’s Growth - The InvestChronicle
Earnings call: BioLineRx beats Q2 goals with strong APHEXDA demand - Investing.com
BioLineRx’s Strong Quarter with APHEXDA Growth - TipRanks
Options Volatility and Implied Earnings Moves Today, August 15, 2024 - TipRanks
Bioline Rx Ltd ADR’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
Ratio Revelations: Bioline Rx Ltd ADR (BLRX)’s Financial Metrics in the Spotlight - The Dwinnex
There is no doubt that Bioline Rx Ltd ADR (BLRX) ticks all the boxes. - SETE News
Bioline Rx Ltd ADR (BLRX) stock analysis: A simple moving average approach - US Post News
BLRX’s Stock Journey: What Investors Need to Know About Bioline Rx Ltd ADR’s Performance - The InvestChronicle
Financial Analysis: Bioline Rx Ltd ADR (BLRX)'s Ratios Unveil Key Insights – DWinneX - The Dwinnex
Bioline Rx Ltd ADR Inc. (BLRX) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
BLRXBioLineRx Reports Second Quarter 2011 Financial Results - br.ADVFN.com
What Can Bioline Rx Ltd ADR (NASDAQ: BLRX) Expect In 2024? – Stocks Register - Stocks Register
Bioline Rx Ltd ADR (BLRX) stock: A year of ups and downs – US Post News - US Post News
Bioline Rx Ltd ADR (BLRX)'s Market Momentum: Closing Strong at 0.69, Down -4.03 – DWinneX - The Dwinnex
BioLineRx Trials New Sickle Cell Gene Therapy - TipRanks
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applicatio - Investing.com India
Understanding the Risks of Investing in Bioline Rx Ltd ADR (BLRX) – Knox Daily - Knox Daily
Earnings call: BioLineRx Q1 2024 results show steady progress - Investing.com India
Earnings call: BioLineRx Q1 2024 results show steady progress By Investing.com - Investing.com
BioLineRx Q1 Success with APHEXDA® Growth - TipRanks
Bioline Rx Ltd ADR (BLRX) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Are Smart Investors Making the Right Decision? Bioline Rx Ltd ADR (BLRX) – Sete News - SETE News
BioLineRx to present new data from CheMo4METPANC Phase 2 at ASCOTipRanks.com - TipRanks
BioLineRx reports positive pancreatic cancer trial results By Investing.com - Investing.com
Ratios Reveal: Breaking Down Bioline Rx Ltd ADR (BLRX)'s Financial Health – DWinneX - The Dwinnex
Examining Bioline Rx Ltd ADR (BLRX) more closely is necessary – US Post News - US Post News
Bioline Rx Ltd Adr (BLRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):